Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors (Q58614608)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Cristina Saura

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Eva Muñoz-Couselo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Josep Tabernero Caturla

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Serena Di Cosimo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

C Serrano

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

L De Mattos-Arruda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Bellet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

P Gómez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

J Pérez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Vidal

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M J Carreras

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

G Sánchez-Ollé

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

J Baselga

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

9 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

897-902

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Clinical cardiac tolerability of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Cancer and aging. An evolving panorama

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Cardiotoxicity profile of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

A general cardiovascular risk profile: The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Cardiac side-effects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Long-Term Trends in the Incidence of and Survival with Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

Role of biomarkers in chemotherapy-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR348

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21828361%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference